Adtalem Global Education Inc.: management transactions · United States · SEC (Form 4)

About Adtalem Global Education Inc.

Adtalem Global Education Inc. (NYSE: ATGE) is a U.S.-based post-secondary education and professional talent company headquartered in Chicago, Illinois, United States. The company traces its roots to the former DeVry Education Group and rebranded to Adtalem in 2017 as it sharpened its strategic focus on healthcare education and workforce development. For investors, Adtalem is best understood not as a broad-based education conglomerate, but as a specialized healthcare talent platform aimed at filling critical labor shortages across nursing, medicine, veterinary medicine and adjacent healthcare fields. ([adtalem.com](https://www.adtalem.com/about-us?utm_source=openai)) Adtalem’s portfolio includes Chamberlain University, Walden University, Ross University School of Medicine, Ross University School of Veterinary Medicine and American University of the Caribbean School of Medicine. Chamberlain is a major nursing education brand in the United States, while Walden provides a larger online and graduate education footprint. The Ross and AUC medical schools expand Adtalem’s exposure to long-duration, highly selective training pathways that benefit from structural demand for physicians and other healthcare professionals. That portfolio mix gives the company a relatively coherent operating model: the common denominator is healthcare, employability and professional advancement. ([adtalem.com](https://www.adtalem.com/institutions-and-companies?utm_source=openai)) From a competitive standpoint, Adtalem has scale in U.S. private healthcare education, a recognizable brand set and a blended delivery model that combines online learning, hybrid instruction and clinical training. The company emphasizes career-relevant programs and partnerships that link education more directly to employment outcomes. Competition comes from public universities, private colleges, online education providers and other healthcare-focused operators, but admissions selectivity, licensing requirements and graduate placement outcomes create meaningful barriers to entry. ([investors.adtalem.com](https://investors.adtalem.com/press-releases/press-releases-details/2025/Adtalem-Global-Education-Third-Quarter-Fiscal-Year-2025-Results-Guidance-Raised/default.aspx?utm_source=openai)) Geographically, Adtalem remains primarily U.S.-anchored, with operations in the United States and an international footprint through certain Caribbean-based medical schools and global student pipelines. Recent highlights have been favorable: for fiscal 2025, the company reported revenue growth, rising total enrollment and improved profitability, while also initiating a share repurchase program and maintaining a strong balance sheet. In 2025 and into fiscal 2026, management highlighted continued enrollment momentum, AI-related healthcare education initiatives and broader pathways into medical school. For investors, Adtalem appears as a healthcare-education name listed on the NYSE with a defensive end-market profile, but one that remains sensitive to regulation, enrollment trends and execution discipline. ([investors.adtalem.com](https://investors.adtalem.com/press-releases/press-releases-details/2025/Adtalem-Global-Education-Announces-Exceptional-Fiscal-Year-2025-Results-Initiates-Fiscal-Year-2026-Guidance/default.aspx?utm_source=openai))